Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. Show more

Location: Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States | Website: https://larimartx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

312.4M

52 Wk Range

$1.61 - $5.37

Previous Close

$3.43

Open

$3.42

Volume

1,633,852

Day Range

$3.38 - $3.72

Enterprise Value

132.2M

Cash

175.4M

Avg Qtr Burn

-24.12M

Insider Ownership

1.10%

Institutional Own.

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.